Eli Lilly said on Thursday that in a late-stage clinical trial, its high-profile weight loss tablets helped patients maintain most of their weight loss results after switching directly from the company's Zepbound injection or Novo Nordisk competitor Wegovy. BMO capital markets analyst Evan Seigerman said the trial's positive results could “present a unique opportunity for Eli Lilly to share revenue share from Novo Nordisk Wegovy and the chronic treatment market for simeglutide, the active ingredient in the diabetes injection Ozempic.”

Eli Lilly said on Thursday that in a late-stage clinical trial, its high-profile weight loss tablets helped patients maintain most of their weight loss results after switching directly from the company's Zepbound injection or Novo Nordisk competitor Wegovy. BMO capital markets analyst Evan Seigerman said the trial's positive results could “present a unique opportunity for Eli Lilly to share revenue share from Novo Nordisk Wegovy and the chronic treatment market for simeglutide, the active ingredient in the diabetes injection Ozempic.”